Biopharmaceutical company Affibody announced a major Nordic study will begin using its ABY-025 PET imaging agent.
ABY-025 is a molecule imaging tracer that can identify HER2 status in breast cancer patients. The researchers of the Affibody-3 study will be investigating a new ABY-025-based method developed at Uppsala University in Sweden and the PET center at Uppsala University Hospital.
ABY-025 finds and attaches to the HER2 protein. The PET camera then records the tracer signals and calculates the patient's exact HER2 status, enabling the physician to prescribe medication more accurately.
In total, 120 women with breast cancer from seven to eight hospitals in Sweden, Denmark, and Finland will be included in the study.
